206551-41-9

Basic information

• Product Name: 3-Bromo-2-fluorobenzoic acid methyl ester
• Synonyms: 3-Bromo-2-fluorobenzoic acid methyl ester;methyl 2-fluoro-3-bromobenzoate
• CAS NO: 206551-41-9
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.04
• Product Categories: Aromatic Esters
• Mol File: 206551-41-9.mol
• Article Data: 13

Chemical Properties

• Melting Point: 35-37℃
• Boiling Point: 255℃
• Flash Point: 108℃
• Appearance: White to cream/Fused Solid
• Density: 1.577
• Vapor Pressure: 0.016mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 3-Bromo-2-fluorobenzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-2-fluorobenzoic acid methyl ester(206551-41-9)
• EPA Substance Registry System: 3-Bromo-2-fluorobenzoic acid methyl ester(206551-41-9)

Safety Data

• Hazardous Substances Data: 206551-41-9(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

InChI:InChI=1/C8H6BrFO2/c1-12-8(11)5-3-2-4-6(9)7(5)10/h2-4H,1H3

Upstream product

• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 1007-16-5 3-bromo-4-fluorobenzoic acid 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 1042055-86-6 methyl 3-((tert-butoxycarbonyl)amino)-2-fluorobenzoate 
• 1389287-37-9 7-(4-aminophenyl)-1H-indazol-3(2H)-one 
• 1389287-38-0 C₂₁H₁₅F₃N₄O₂ 
• 939024-44-9 2-fluoro-3-(pyridine-2-yl)benzoic acid trifluoroacetate 
• 77771-03-0 3-bromo-4-fluoro-benzyl alcohol 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 1195767-92-0 N-{3-[2-(1-amino-1-methylethyl)-5-(2-methyl-4-pyrimidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195767-56-6 N-({4-[4-(3-{[(2,5-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-2-(4-morpholinyl)-1,3-thiazol-5-yl]-2-pyrimidinyl}methyl)cyclopentanecarboxamide 
• 1195769-66-4 1,1-dimethylethyl 4-[5-(2-amino-4-pyrimidinyl)-4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-1,3-thiazol-2-yl]-4-methyl-1-piperidinecarboxylate 
• 1195769-64-2 1,1-dimethylethyl 4-[5-(2-chloro-4-pyrimidinyl)-4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-1,3-thiazol-2-yl]-4-methyl-1-piperidinecarboxylate 
• 1195769-74-4 1,1-dimethylethyl 4-[5-(2-amino-4-pyrimidinyl)-4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-1,3-thiazol-2-yl]-1-piperidinecarboxylate 
• 1195767-57-7 N-({4-[4-(3-{[(2,5-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-2-(4-morpholinyl)-1,3-thiazol-5-yl]-2-pyrimidinyl}methyl)-2-methylpropanamide 
• 1195769-72-2 1,1-dimethylethyl 4-[5-(2-chloro-4-pyrimidinyl)-4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-1,3-thiazol-2-yl]-1-piperidinecarboxylate 
• 1195767-55-5 2,5-difluoro-N-{2-fluoro-3-[5-(2-{[(methylsulfonyl)amino]methyl}-4-pyrimidinyl)-2-(4-morpholinyl)-1,3-thiazol-4-yl]phenyl}benzenesulfonamide 

Relevant articles and documents

Enantioselective Total Synthesis of Beraprost Using Organocatalyst

A convergent and enantioselective total synthesis of the most active isomer of beraprost was achieved in 17 pots. A unique tricyclic core in beraprost was synthesized efficiently by utilizing the asymmetric organocatalyst-mediated formal [3 + 2] cycloaddi

Discovery of dabrafenib: A selective inhibitor of Raf Kinases with antitumor activity against B-Raf-driven tumors

Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been observed in a number of human tumors, including melanomas. Herein we report the discovery and biological evaluation of GSK2118436, a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-RafV600E human melanoma. GSK2118436 was identified as a development candidate, and early clinical results have shown significant activity in patients with B-Raf mutant melanoma.

TRICYCLIC INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein X, Y, Z, R3 and R4 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.